AI Article Synopsis

  • Intensive glycemic control was found to reduce coronary artery disease (CAD) events in participants with the haptoglobin (Hp)2-2 phenotype in the ACCORD study, but not in those without this phenotype.
  • In the ADVANCE study, researchers evaluated the impact of intensive glycemic control on CAD risk, finding no significant benefits for participants with or without the Hp2-2 phenotype overall, but a notable risk reduction in Hp2-2 participants without prior cardiovascular disease.
  • The study concludes that intensive glycemic control may specifically help prevent major CAD events in individuals with the Hp2-2 phenotype who have no history of cardiovascular disease.

Article Abstract

Objective: Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study participants with the haptoglobin (Hp)2-2 phenotype but not in participants without the Hp2-2 phenotype. It is unknown whether and how these results translate across different demographic/clinical characteristics and treatment strategies.

Research Design And Methods: Haptoglobin phenotype was measured in available samples from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) biomarker case-cohort study. Weighted multivariable-adjusted Cox regression models were used to evaluate the association between intensive glycemic control (HbA1c target of ≤6.5%) versus standard therapy (based on local guidelines) and major CAD events among participants with (n = 1,327) and without (n = 2,077) the Hp2-2 phenotype separately and within prespecified stratifications by sex, race, previous cardiovascular disease (CVD), diabetes duration, and HDL-cholesterol.

Results: While the hazard ratios (HRs) were in the hypothesized differing directions, compared with standard therapy, intensive glycemic control was not significantly associated with risk of CAD events among participants without (1.04, 95% CI 0.82-1.32) or with (0.84, 0.63-1.14, Pinteraction = 0.27) the Hp2-2 phenotype overall. Intensive therapy was associated with lower CAD risk among participants with the Hp2-2 phenotype who had no previous CVD (0.47, 0.29-0.76, Pinteraction = 0.01).

Conclusions: Our findings suggest that intensive glycemic control contributes to the prevention of major CAD events among ADVANCE participants with the Hp2-2 phenotype and no previous CVD and are in alignment with our hypothesis that intensive glycemic control may be beneficial in a subset of people with the Hp2-2 phenotype.

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc23-2165DOI Listing

Publication Analysis

Top Keywords

hp2-2 phenotype
28
intensive glycemic
24
glycemic control
24
cad events
16
participants hp2-2
12
haptoglobin phenotype
8
phenotype intensive
8
coronary artery
8
artery disease
8
phenotype
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!